Clinical Attribute

Arcturus Therapeutics Stock Crashes 60% on Underwhelming mRNA Cystic Fibrosis Drug Results

5 days ago talkbio0Tagged ARCT-032, Arcturus Therapeutics ', clinical trial results, Cystic Fibrosis, mRNA therapy, Respiratory physiology, safety profile, Stock Crash, Volume^at 1.0 s post forced expiration:Volume:Point in time:Respiratory system:Quantitative

Arcturus Therapeutics; ARCT-032; cystic fibrosis; mRNA therapy; stock crash; clinical trial results; lung function; FEV1; safety profile

ESMO Spotlight: Flagship ADCs move into early-stage cancer to validate chemo-displacement ambitions

5 days ago talkbio0Tagged 2025, ADCs, Administration occupational activities, Antibody-Drug Conjugates, Biological Markers, chemo-displacement, Datopotamab deruxtecan, Datroway, Enhertu, ESMO, HER2-positive, Limited stage (cancer stage), Malignant neoplasm of breast, Toxicity aspects, trastuzumab, Triple Negative Breast Neoplasms

ESMO 2025; antibody-drug conjugates; ADCs; early-stage cancer; chemo-displacement; trastuzumab deruxtecan; ENHERTU; datopotamab deruxtecan; DATROWAY; breast cancer; HER2-positive; triple-negative breast cancer; biomarkers; toxicity management

Lunit AI Predicts Immunotherapy Outcomes in Colorectal, Kidney, and Lung Cancer at ESMO 2025

2 weeks ago talkbio0Tagged Biological Markers, Colorectal Carcinoma, Immunotherapy, Lunit AI, Malignant neoplasm of kidney, Malignant neoplasm of lung, Pathology, SCOPE IO, treatment prediction

Lunit AI; SCOPE IO; immunotherapy; colorectal cancer; kidney cancer; lung cancer; biomarkers; ESMO 2025; treatment prediction; AI pathology

FDA Considers Noninvasive Endpoint for MASH Trials, Boosts Biotech Shares

2 months ago talkbio0Tagged Altimmune, Biological Markers, Clinical Trials, Inventiva, Liver diseases, Madrigal Pharmaceuticals, MASH, Noninvasive Endpoint, stocks, United States Food and Drug Administration, Viking Therapeutics

FDA; noninvasive endpoint; liver disease; MASH; clinical trials; biomarker; biotech stocks; Madrigal Pharmaceuticals; Viking Therapeutics; Inventiva; Altimmune

Personalizing Metabolic Care with Digital Twins: Recent Developments

2 months ago talkbio0Tagged Administration occupational activities, Artificial Intelligence, Biological Markers, Diabetes, digital twins, Glucagon-Like Peptide 1, Health care facility, metabolic health, Obesity, Precision Medicine, real-time guidance, Reversal, Twin Health

digital twins; metabolic health; AI healthcare; personalized medicine; biomarkers; diabetes management; obesity reversal; real-time guidance; GLP-1; Twin Health

AI, Media and the Evolution of Omnichannel in Healthcare Marketing — Ray Rosti on Episode 3 of The Next Marketing with HJ

3 months ago talkbio0Tagged Artificial Intelligence, Automation, Biomechanical compliance, Communications Media, connected journeys, content intelligence, Doceree, Engaged to be married, Health Care Market, Hereditary Coproporphyria, Klick Media, Measurement, omnichannel, Optimization, personalization, Pharma, Privacy, Region of interest:Presence or Identity:Point in time:*:Nominal

AI in healthcare marketing; omnichannel; first‑party data; content intelligence; media optimization; privacy and compliance; measurement and ROI; pharma marketing; Klick Media; Doceree; HCP engagement; personalization; automation; connected journeys

Roche Doubles Down on Alzheimer’s with Next-Gen Amyloid-Lowering Drug Trontinemab

3 months ago talkbio0Tagged Alzheimer 's disease, amyloid-lowering drug, Biological Markers, Brainshuttle, Drug Development, Interventional procedure, Phase 3 Clinical Trials, Roche (company), TRONTIER, Trontinemab

Roche; Alzheimer’s disease; trontinemab; amyloid-lowering drug; Brainshuttle; Phase III trial; TRONTIER studies; drug development; biomarkers; early intervention

Advancements in Predicting Tumor Response and Expanding Therapy Eligibility Using Epigenomic Biomarkers

3 months ago talkbio0Tagged Biological Markers, Diagnostics, DNA Methylation, Epigenomics, personalized cancer therapy, Prediction, tumor response

epigenomic biomarkers; tumor response prediction; personalized cancer therapy; DNA methylation; AI-driven diagnostics

ALTO-203 Misses Depression Endpoint but Shows Positive Biomarker and Cognitive Signals

4 months ago talkbio0Tagged ALTO-203, Attention, Biological Markers, development aspects, drug activity, Electroencephalography, Neuroscience discipline, theta/beta ratio, Wakefulness, William Blair

ALTO-203; Alto Neuroscience; Phase 2 trial; major depressive disorder; EEG biomarkers; theta/beta ratio; attention; wakefulness; William Blair; drug activity; future development

Recent Developments in Immune Profiling for Early Immuno-Oncology Trials

4 months ago talkbio0Tagged Artificial Intelligence, Biological Markers, Clinical Trials, Discover, immune profiling, immuno-oncology, Immunotherapy, microenvironment, multi-omic strategies, Neoplasms, Precision Medicine, spatial proteomics

immune profiling; immuno-oncology; clinical trials; AI in immunotherapy; multi-omic strategies; tumor microenvironment; spatial proteomics; biomarker discovery; personalized medicine